SCHEMBL30133773

SCHEMBL30133773

CC(O)c1ccc2ccncc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
UGT2B7 P16662 1/20 0.58
PLG P00747 1/20 0.44
PLAU P00749 1/20 0.44
PRKCZ Q05513 1/20 0.43
CYP2D6 P10635 8/20 0.43
CYP3A4 P08684 7/20 0.43
SLC6A2 P23975 7/20 0.43
SLC6A4 P31645 7/20 0.43
SLC6A3 Q01959 7/20 0.43
KCNH2 Q12809 7/20 0.43
MELK Q14680 1/20 0.42
ROCK2 O75116 3/20 0.39
MEN1 O00255 1/20 0.39
CYP1A2 P05177 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39
HIF1A Q16665 1/20 0.39
CYP11B1 P15538 1/20 0.38
CYP11B2 P19099 1/20 0.38
CYP19A1 P11511 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3128980 0.93 UGT2B7 (0.58) UGT2B7PLGPLAUCYP2D6CYP3A4
SCHEMBL2611067 0.86 PRKCZ (0.52) UGT2B7PRKCZCYP2D6CYP3A4SLC6A2
SCHEMBL23479835 0.81 PRKCZ (0.43) UGT2B7PRKCZCYP2D6CYP3A4SLC6A2
SCHEMBL12769692 0.81 PRKCZ (0.47) UGT2B7PRKCZCYP2D6CYP3A4SLC6A2
SCHEMBL27524276 0.81 PRKCZ (0.43) UGT2B7PRKCZCYP2D6CYP3A4SLC6A2
SCHEMBL30087223 0.81 PRKCZ (0.46) UGT2B7PRKCZCYP2D6CYP3A4SLC6A2
SCHEMBL1266869 0.81 PRKCZ (0.46) UGT2B7PRKCZCYP2D6CYP3A4SLC6A2
SCHEMBL30564493 0.80 AKR1C3 (0.54) CYP1A2TSHR
SCHEMBL22453895 0.79 PRKCZ (0.62) PRKCZCYP2D6CYP3A4SLC6A2SLC6A4
SCHEMBL27256471 0.79 ALDH1A1 (0.42) PRKCZCYP2D6CYP3A4SLC6A2SLC6A4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-119119033-A Pyrazolopyridone compounds 百济神州有限公司 2024-12-13 CN disclosed
US-20240300951-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-09-12 US disclosed
US-20240270751-A1 Pyrazolopyridinone Compounds BEIGENE LTD. (KY) 2024-08-15 US disclosed
EP-4380936-A1 PYRAZOLOPYRIDINONE COMPOUNDS BeiGene, Ltd. (KY) 2024-06-12 EP disclosed
CN-117836296-A Pyrazolopyridone compounds 百济神州有限公司 2024-04-05 CN disclosed
WO-2023011456-A1 PYRAZOLOPYRIDINONE COMPOUNDS BEIGENE, LTD. (KY) 2023-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240300951-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK UGT2B7 2079/4885PLG 3934/4885PLAU 3631/4885
US-20240270751-A1 Pyrazolopyridinone Compounds NFATC1, CD4, PBK UGT2B7 2079/4885PLG 3934/4885PLAU 3631/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.